292 related articles for article (PubMed ID: 30999307)
1. Is the Renin-Angiotensin-Aldosterone System Good for the Kidney in Acute Settings?
Dudoignon E; Dépret F; Legrand M
Nephron; 2019; 143(3):179-183. PubMed ID: 30999307
[TBL] [Abstract][Full Text] [Related]
2. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
Ruiz-Hurtado G; Ruilope LM
Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
[TBL] [Abstract][Full Text] [Related]
3. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
Remuzzi G; Perico N; Macia M; Ruggenenti P
Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
[TBL] [Abstract][Full Text] [Related]
4. [Renin-angiotensin-aldosterone system (RAAS) and its pharmacologic modulation].
Giestas A; Palma I; Ramos MH
Acta Med Port; 2010; 23(4):677-88. PubMed ID: 20687997
[TBL] [Abstract][Full Text] [Related]
5. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
[TBL] [Abstract][Full Text] [Related]
6. The renin-angiotensin-aldosterone system and its suppression.
Ames MK; Atkins CE; Pitt B
J Vet Intern Med; 2019 Mar; 33(2):363-382. PubMed ID: 30806496
[TBL] [Abstract][Full Text] [Related]
7. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease.
Gupta G; Dahiya R; Singh Y; Mishra A; Verma A; Gothwal SK; Aljabali AAA; Dureja H; Prasher P; Negi P; Kapoor DN; Goyal R; Tambuwala MM; Chellappan DK; Dua K
Chem Biol Interact; 2020 Feb; 317():108975. PubMed ID: 32032593
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
Mercier K; Smith H; Biederman J
Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
[TBL] [Abstract][Full Text] [Related]
10. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
12. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Black HR
Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
14. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
15. Antifibrotic Roles of RAAS Blockers: Update.
Zhang YY; Yu Y; Yu C
Adv Exp Med Biol; 2019; 1165():671-691. PubMed ID: 31399990
[TBL] [Abstract][Full Text] [Related]
16. Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?
Lattanzio MR; Weir MR
Curr Hypertens Rep; 2010 Oct; 12(5):369-77. PubMed ID: 20703958
[TBL] [Abstract][Full Text] [Related]
17. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
Li SM; He WB; Chen J; Cai QQ; Huang FF; Zhang K; Wang JF; Liu X; Huang H
Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
[TBL] [Abstract][Full Text] [Related]
18. The renin-angiotensin-aldosterone system and heart failure.
Sayer G; Bhat G
Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
[TBL] [Abstract][Full Text] [Related]
19. Effects of RAAS Inhibitors in Patients with Kidney Disease.
Zhang F; Liu H; Liu D; Liu Y; Li H; Tan X; Liu F; Peng Y; Zhang H
Curr Hypertens Rep; 2017 Aug; 19(9):72. PubMed ID: 28791529
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
Weinberger MH; Luft FC
Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
